Browsing Tag
Panadol
3 posts
HLN share price firms as Sensodyne and Centrum drive Haleon’s 2026 organic growth recovery
Sensodyne grows 8%. Centrum targets GLP-1 users. The £500m buyback erases shares at sub-340p. Haleon's recovery hinges on Q2 cold and flu normalising.
Haleon (HLN) Q1 2026 results: Can Sensodyne and parodontax offset weak cold and flu demand?
Haleon’s cold and flu drag is testing growth. Sensodyne, parodontax and margin discipline may decide whether HLN can regain momentum.
Haleon plc (LON: HLN) FY2025 results: Can margin expansion, operating model reform, and capital discipline overcome weak North American demand?
Haleon plc posts 3% organic growth and 10.5% profit expansion in FY2025. Can margin gains and buybacks drive stronger returns in 2026? Read more.